On the recordJuly 15, 2013
Under the proposed Senate framework, FDA would be barred from requiring compounding manufacturers to submit NDAs and ANDAs pre-inspection and labeling requirements before these drugs reach patients.
Source
congress.govEditor's note · Context
Pitts highlights concerns about FDA's regulatory limitations on compounding manufacturers.
Share
More from Joe Pitts
Sep 13, 2016
if they expanded Medicaid 50,000 of my constituents would have Medicaid, if the state expanded it.
Sep 7, 2016
H.R. 1807, the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015, sponsored by Rep. Danny Davis (IL) and Rep. Michael Burgess (TX) reauthorizes a sickle cell disease demonstration program.
Dec 6, 2016
Both the FDA and the General Accountability Office agree that there is no food safety justification for this regulatory divide.
Dec 6, 2016
It seems illogical that the USDA would be given the exclusive authority to oversee and regulate catfish only while the FDA regulates all other seafood.
Other voices in this conversation
